Infectious Disease Research Institute

The Access to Advanced Health Institute Receives up to $12.7 Million to Develop Novel NanoAlum Adjuvant Formulation for Better Protection Against Tuberculosis and Pandemic Influenza

Retrieved on: 
Thursday, March 7, 2024
COVID-19, Research, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Hepatitis A, Senior, Infectious Disease Research Institute, Immune system, Toxicology, Doctor of Philosophy, Medicine, Multimedia, TLR, Government, Infection, Access, Defense, RTS, Vaccine, Notifiable disease, Shingles, Malaria, Unitary state, Respiratory syncytial virus, Formulation, Fungus, MPH, MCDC, Disease, Tuberculosis, OTA, Parasitism, HIV, Cancer

View the full release here: https://www.businesswire.com/news/home/20240307661956/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307661956/en/
    This five-year prototype project will support AAHI’s development and optimization of “NanoAlum” – a novel nanoparticle adjuvant formulation, made from aluminum salts (“alum”).
  • Alum-adjuvanted vaccines have been less effective against diseases such as tuberculosis and influenza, which are more complex to target and can be challenging to manufacture because they require special sterilization methods.
  • AAHI’s NanoAlum formulation changes the size, shape, and charge of alum particles to enhance specific immune responses for better vaccine protection against complex diseases.
  • AAHI’s prototype project for MCDC will pair the combined 3M-052 and NanoAlum formulation with tuberculosis and pandemic influenza vaccine antigens.

The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial

Retrieved on: 
Thursday, August 3, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Vaccine, Human, Award, Fungus, National Institute of Allergy and Infectious Diseases, Fever, COVID-19, Mosquito-borne disease, Principal investigator, Cancer, NIH, Unitary state, Parasitism, Chikungunya, Multimedia, Temperature, Research, Infection, Cell, RNA, Doctor of Philosophy, Government, Bangladesh Technical Education Board, Rash, Science, Messenger, Infectious Disease Research Institute, Animal, Notifiable disease, Access, NLC, Immune system, Disease, Knowledge, Mortality, Geography, FDA, Headache, Virus

The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.

Key Points: 
  • The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.
  • AAHI’s approach to an RNA vaccine against chikungunya is distinctly different from the RNA vaccines which are currently approved by the FDA to prevent other diseases.
  • View the full release here: https://www.businesswire.com/news/home/20230803141024/en/
    AAHI RNA vaccine team evaluating preclinical data in the AAHI laboratory in Seattle, WA.
  • The goal of the award is to develop an effective chikungunya vaccine candidate that can reach endemic areas of the world.

The Access to Advanced Health Institute Reports Encouraging Results of First-In-Human Trial of Its Temperature-Stable Tuberculosis Vaccine Candidate

Retrieved on: 
Monday, March 6, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Senior, Parasitism, Principal, Protein, Infectious Disease Research Institute, World Health Organization, Infection, Vaccine, Biocatalysis, Bangladesh Technical Education Board, NIH, Tuberculosis, Mycobacterium tuberculosis, Saint Louis University, Antibody, MPH, Laboratory, University, Refrigeration, Unitary state, Cancer, Access, Disease, Atmosphere, Multimedia, Government, Immune system, COVID-19, Notifiable disease, Doctor of Philosophy, Safety, Fungus, NIAID, MD, TB

The Access to Advanced Health Institute (AAHI) published results of a Phase 1 clinical trial demonstrating the safety and immune responses in a new vaccine against tuberculosis (TB), the world’s second deadliest infectious disease ( NCT03722472 ).

Key Points: 
  • The Access to Advanced Health Institute (AAHI) published results of a Phase 1 clinical trial demonstrating the safety and immune responses in a new vaccine against tuberculosis (TB), the world’s second deadliest infectious disease ( NCT03722472 ).
  • The novel single-vial presentation of this freeze-dried TB vaccine candidate elicited a stronger immune response than administration of the same vaccine using separate vials of antigen and liquid adjuvant formulation.
  • AAHI’s single-vial TB vaccine candidate represents significant progress in global efforts to combat TB.
  • By reducing the need for cold chain, AAHI’s TB vaccine candidate may significantly advance the global fight against TB.

The Access to Advanced Health Institute Announces $3M Award to Develop an Intranasal Pan-Viral Countermeasure against Respiratory Viruses

Retrieved on: 
Wednesday, February 15, 2023
Research, General Health, Contracts, Pharmaceutical, Infectious Diseases, Defense, Clinical Trials, Science, COVID-19, Other Science, Health, Military, Unitary state, Defense Innovation Unit, DIU, OTA, Urinary tract infection, Acceleration, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Hospital, Human, United States Department of Defense, Virus, TLR, Parasitism, Immunity, Infectious Disease Research Institute, Joint Program Executive Office Chemical and Biological Defense, Safety, JPM, Government, Patient, Access, SLA, Temperature, Nipah virus, TLR4, Immune system, Amoebiasis, Fungus, VAMP, Disease, Notifiable disease, Multimedia, Principal, Cancer, Vaccine, Chemical substance, Radiation

AAHI will be working with the DIU and JPM CBRN Medical to develop a prototype nasal spray using AAHI’s novel formulation of two adjuvants, substances that enhance immune responses.

Key Points: 
  • AAHI will be working with the DIU and JPM CBRN Medical to develop a prototype nasal spray using AAHI’s novel formulation of two adjuvants, substances that enhance immune responses.
  • AAHI’s adjuvant formulation platform enables development of temperature-stable products that can be easily distributed and stored to support the health and safety of warfighters.
  • AAHI will use its adjuvant formulation platform to develop a prototype product that promises to shorten timelines for emergency response to and mitigate impacts from biological threats.
  • AAHI’s collaboration with the DoD will build on AAHI’s over two decades of formulation expertise and broad portfolio of adjuvant formulations.

Codexis Announces Appointment of H. Stewart Parker to Board of Directors

Retrieved on: 
Tuesday, December 20, 2022
Corporate development, Executive Committee, Therapy, Tropical disease, Literature, Language, International business, University of Washington Department of Bioengineering, BIO, Infectious Disease Research Institute, University, Genetics, IDRI, Diagnosis, Management, Codexis

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.
  • Since 2014, Ms. Parker has served on the Board of Directors of IMPEL Pharmaceuticals Inc., a publicly traded pharmaceutical company and Sangamo Therapeutics, Inc., a publicly traded genomic therapies company.
  • Ms. Parker also currently serves on the Board of Directors of private gene therapy company StrideBio, Inc.
  • in Slavic Language and Literature and an M.B.A. in Finance and International Business from the University of Washington.

The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

Retrieved on: 
Wednesday, November 2, 2022
COVID-19, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, RNA, MD, Face, SaRNA, COVID, Science, Partnership, Clinical trial, Cancer, Research, Infectious Disease Research Institute, Degenerative disease, COVID-19, Disease, Immune system, Immunodeficiency, Transport, Government, Fungus, NPJ, Technology, NLC, Vaccine, Temperature, Access, Severe acute respiratory syndrome coronavirus 2, Parasitism, Solution, ImmunityBio

Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.

Key Points: 
  • Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.
  • AAHIs RNA vaccines can easily be freeze-dried for long-term room temperature or refrigerated stability (10+ months).
  • The SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is currently being evaluated in liquid form in a first-in-human Phase 1 / 2 clinical trial sponsored by ImmunityBio in South Africa ( NCT05370040 ).
  • The improved temperature stability of AAHI-SC2 enables more equitable access to COVID RNA vaccines, especially in rural and remote communities where resources are limited.

The Access to Advanced Health Institute Receives $26 Million Donation from the Chan Soon-Shiong Family Foundation to Further Develop Immune-Enhancing Platform Technology

Retrieved on: 
Monday, April 11, 2022
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Infectious Diseases, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, LinkedIn, Temperature, Vaccination, Infectious Disease Research Institute, Degenerative disease, Clinical trial, Growth, Coronavirus, Access, Culture, Geography, Vaccine, Research, Fungus, Parasitism, MPH, Chan, Cancer, CEO, RNA, Immunity, Health, Immune system, Technology, RNA transfection, COVID-19, Allergy, Infection, Science, Solution, COVID, Patient, Disease, Immunization, Pharmaceutical industry, MD

This catalytic funding will allow AAHIs dedicated team of expert and innovative scientists to combat the worlds deadliest diseases.

Key Points: 
  • This catalytic funding will allow AAHIs dedicated team of expert and innovative scientists to combat the worlds deadliest diseases.
  • AAHIs formulations and RNA immune-enhancing platforms enable more potent, broadly effective, and longer lasting vaccines and immunotherapies by improving the bodys natural response to disease.
  • AAHIs adjuvant and RNA technology can be applied to infectious diseases, cancer, allergies, fungal and parasitic infections, and other non-communicable diseases.
  • Our proprietary design and product development capabilities make safe and effective solutions more affordable, customizable, and faster and easier to mass produce.

Infectious Disease Research Institute Exits Receivership and Launches AAHI, the Access to Advanced Health Institute, with $50 Million Funding Commitment

Retrieved on: 
Wednesday, March 2, 2022
Health, Infectious Diseases, Practice Management, Other Health, Research, Science, Biotechnology, Drive, Medicine, Nature, RNA, Board, COVID-19, Allergy, Disease, University of Oxford, Infectious Disease Research Institute, IDRI, Degenerative disease, Biomedical Advanced Research and Development Authority, Vaccine, White House, MPH, Government, South African Medical Research Council, LinkedIn, Solution, Development, Needle, CEO, Division, Non-governmental organization, Access, COVID, Director, Oxford, OMS, Temperature, Medical degree, Parasitism, Technology, Coronavirus, Immune system, Fungus, Physician, Doctor of Science, Immunotherapy, Science, University, Board of directors, Geography, Glas, Cancer, CBE, Health, BARDA, Pharmaceutical industry, Management, MD, Research, ImmunityBio

AAHI will continue with the direction and guidance of its new Board of Directors and executive team on solid financial footing.

Key Points: 
  • AAHI will continue with the direction and guidance of its new Board of Directors and executive team on solid financial footing.
  • AAHI launches with multi-year commitments for over $50 million dollars, including recent licensing agreements with partners such as the prominent immunotherapy company ImmunityBio, Inc.
  • Our new name, Access to Advanced Health Institute, reflects our ongoing emphasis on advancing science that enables global equitable access to effective, efficient, broad, and durable vaccines and therapeutics.
  • For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the bodys natural response to disease.

Announcement of Upcoming Launch of Access to Advanced Health Institute and The AAAH Coalition

Retrieved on: 
Wednesday, January 19, 2022
Oncology, Health, Infectious Diseases, General Health, Research, Science, Research, Coalition, Infectious Disease Research Institute, Health, University of Cape Town, Access, Patrick Soon-Shiong, Science, CEO, Emory University, Solution, Disease, Chan, Baylor University, GMP, Goal, Compassion, University of the Witwatersrand, Stellenbosch University, NantWorks, Advance healthcare directive, MPH, AAAH, University, COVID, Pharmaceutical industry, MD

Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).

Key Points: 
  • Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).
  • The AAAH Coalition is supported through several billion rand funding from Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantWorks, and from the Chan Soon-Shiong Family Foundation.
  • With the technologies and facilities AAHI brings to the AAAH coalition, we can transform that commitment into real change for the people of Africa."
  • Our name, Access to Advanced Health Institute, reflects our ongoing emphasis on advancing science that enables global access to effective, efficient, broad, and durable preventive and therapeutic solutions.

Infectious Disease Research Institute Awarded BARDA Funding for Development of Intranasal Influenza RNA Vaccine

Retrieved on: 
Tuesday, December 14, 2021
Infectious Diseases, Biotechnology, Health, Infectious Disease Research Institute, Process, RNA, Biomedical Advanced Research and Development Authority, BARDA, Development, Doctor of Philosophy, IDRI, United States Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, COVID-19, Vaccine, Drive, Department, Refrigeration, Developing country, Division, Hotel manager, Assistant, Research

The Infectious Disease Research Institute (IDRI) , a Seattle-based non-profit biotech research institute, announced today a contract with the Biomedical Advanced Research and Development Authority (BARDA) DRIVe (Division of Research, Innovation, and Ventures) Beyond the Needle program to develop an intranasally delivered RNA vaccine for pandemic influenza.

Key Points: 
  • The Infectious Disease Research Institute (IDRI) , a Seattle-based non-profit biotech research institute, announced today a contract with the Biomedical Advanced Research and Development Authority (BARDA) DRIVe (Division of Research, Innovation, and Ventures) Beyond the Needle program to develop an intranasally delivered RNA vaccine for pandemic influenza.
  • Beyond the Needle funds the development of new technologies to make vaccine and therapeutic administration easier, to ultimately create globally accessible vaccines.
  • The development of an intranasally administered flu vaccine using IDRIs RNA vaccine platform could improve RNA vaccine protection against respiratory viruses, remove the need for the deep cold chain that makes RNA vaccines inaccessible to low-and-middle income countries (LMICs), and alleviate fears in needle-hesitant individuals.
  • BARDA entered into a contract with IDRI for the development of an intranasal RNA vaccine platform with long-term storage stability using H5N1 influenza as an initial proof-of-concept target.